AP-18 is primarily used in scientific research as a selective inhibitor of TRPA1 channels, which are involved in the sensation of pain and inflammation. It is widely applied in studies to understand the role of these channels in pain perception, neurogenic inflammation, and other physiological processes. Researchers utilize AP-18 to explore potential therapeutic targets for conditions like chronic pain, migraines, and inflammatory disorders. Its application helps in elucidating the mechanisms of TRPA1-mediated signaling pathways, contributing to the development of novel treatments for sensory and pain-related disorders.